JP2018513155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513155A5 JP2018513155A5 JP2017553926A JP2017553926A JP2018513155A5 JP 2018513155 A5 JP2018513155 A5 JP 2018513155A5 JP 2017553926 A JP2017553926 A JP 2017553926A JP 2017553926 A JP2017553926 A JP 2017553926A JP 2018513155 A5 JP2018513155 A5 JP 2018513155A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- composition
- patient
- administered
- hrg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000048238 Neuregulin-1 Human genes 0.000 claims description 32
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 32
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 32
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000009121 systemic therapy Methods 0.000 claims description 13
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 6
- 229960005079 pemetrexed Drugs 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 238000007901 in situ hybridization Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 238000005549 size reduction Methods 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000002250 progressing effect Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149271P | 2015-04-17 | 2015-04-17 | |
| US62/149,271 | 2015-04-17 | ||
| PCT/US2016/027933 WO2016168730A1 (en) | 2015-04-17 | 2016-04-15 | Combination treatments with seribantumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513155A JP2018513155A (ja) | 2018-05-24 |
| JP2018513155A5 true JP2018513155A5 (https=) | 2019-05-23 |
Family
ID=55854801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553926A Withdrawn JP2018513155A (ja) | 2015-04-17 | 2016-04-15 | セリバンツマブを用いた併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160303232A1 (https=) |
| EP (1) | EP3283068A1 (https=) |
| JP (1) | JP2018513155A (https=) |
| KR (1) | KR20170137886A (https=) |
| CN (1) | CN107750165A (https=) |
| AU (1) | AU2016248329A1 (https=) |
| CA (1) | CA2983008A1 (https=) |
| EA (1) | EA201792294A1 (https=) |
| HK (2) | HK1250626A1 (https=) |
| IL (1) | IL255092A0 (https=) |
| MA (1) | MA45420A (https=) |
| SG (1) | SG11201708491PA (https=) |
| WO (1) | WO2016168730A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017161009A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment |
| JP7305543B2 (ja) * | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング， インコーポレイテッド | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2021530223A (ja) | 2018-07-09 | 2021-11-11 | スロゼン， インコーポレイテッド | 組織特異性Ｗｎｔシグナル増強分子及びその使用 |
| TW202233656A (zh) | 2020-11-16 | 2022-09-01 | 美商蘇羅森營運公司 | 肝特異性wnt訊號增強分子及其用途 |
| CN115976196B (zh) * | 2022-12-16 | 2024-12-06 | 深圳市人民医院 | ErbB3作为肺动脉高压生物标志物和治疗靶点的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2592177A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| ES2511218T5 (es) | 2005-06-20 | 2017-12-07 | Advanced Cell Diagnostics, Inc. | Kits y productos para detección de ácidos nucleicos en células individuales y para identificación de células raras en grandes poblaciones de células heterogéneas |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| UA104868C2 (uk) | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
| CA2792327C (en) | 2010-03-11 | 2019-09-24 | Merrimack Pharmaceuticals, Inc. | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| EP2590654B1 (en) * | 2010-07-09 | 2016-12-21 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
| WO2012103341A1 (en) | 2011-01-27 | 2012-08-02 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid stage tumors using anti-erbb3 antibodies |
| US20140134170A1 (en) | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| SG192775A1 (en) * | 2011-03-15 | 2013-09-30 | Merrimack Pharmaceuticals Inc | Overcoming resistance to erbb pathway inhibitors |
| EP2726100A4 (en) | 2011-06-30 | 2015-04-29 | Merrimack Pharmaceuticals Inc | ANTIBODIES TO ERBB3 IN COMBINATION WITH PACLITAXEL FOR THE TREATMENT OF GYNECOLOGICAL CANCER TYPES |
| AU2012294326A1 (en) | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
| AU2013201584A1 (en) | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
| TW201601754A (zh) * | 2013-09-30 | 2016-01-16 | 第一三共股份有限公司 | 核酸生物標記及其用途 |
| EP3087394A2 (en) * | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
-
2016
- 2016-04-15 CA CA2983008A patent/CA2983008A1/en not_active Abandoned
- 2016-04-15 AU AU2016248329A patent/AU2016248329A1/en not_active Abandoned
- 2016-04-15 KR KR1020177033074A patent/KR20170137886A/ko not_active Withdrawn
- 2016-04-15 CN CN201680035146.7A patent/CN107750165A/zh active Pending
- 2016-04-15 HK HK18110002.5A patent/HK1250626A1/zh unknown
- 2016-04-15 EA EA201792294A patent/EA201792294A1/ru unknown
- 2016-04-15 MA MA045420A patent/MA45420A/fr unknown
- 2016-04-15 JP JP2017553926A patent/JP2018513155A/ja not_active Withdrawn
- 2016-04-15 HK HK18108183.0A patent/HK1248539A1/zh unknown
- 2016-04-15 EP EP16718955.4A patent/EP3283068A1/en not_active Withdrawn
- 2016-04-15 SG SG11201708491PA patent/SG11201708491PA/en unknown
- 2016-04-15 WO PCT/US2016/027933 patent/WO2016168730A1/en not_active Ceased
- 2016-05-17 US US15/156,603 patent/US20160303232A1/en not_active Abandoned
-
2017
- 2017-10-17 IL IL255092A patent/IL255092A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513155A5 (https=) | ||
| RU2017125053A (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| Srinivasan et al. | Head and Neck | |
| Arrondeau et al. | LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non–Small-Cell Lung Cancer | |
| Guigay et al. | Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance | |
| Shah et al. | Head and neck | |
| Singh et al. | Gefitinib plus docetaxel in non-small-cell lung cancer | |
| Laughlin et al. | Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer | |
| Hockings et al. | Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer | |
| JP2019508032A5 (https=) | ||
| Peng et al. | MA14. 01 Clinical and Genomic Features of Chinese Lung Cancer Patients with Germline Mutations | |
| Reni | Evidences and opinions for adjuvant therapy in pancreatic cancer | |
| Lim et al. | 65: Maintenance pemetrexed for non-squamous non-small cell lung cancer (NSCLC):‘real life’outcomes from a UK centre | |
| Sun et al. | 466P Gefitinib retreatment beyond progression in advanced NSCLC patients with sensitive EGFR mutations | |
| Wang et al. | 9124 POSTER Nimotuzumab in Combination With Chemotherapy in the Patients With Advanced Non-small Cell Lung Cancer | |
| Gupta et al. | Head and Neck | |
| Das et al. | Head and neck | |
| Khurana et al. | Head and Neck | |
| Petrelli et al. | 9126 POSTER Anaemia Risk With Anti-EGFR Agents in Advanced Non Small Cell Lung Cancer–a Meta-analysis of 10 Trials | |
| Pujari et al. | Head and Neck | |
| Raturi et al. | Head and Neck | |
| Vijayakumar | Head and Neck | |
| Mishra et al. | Head and Neck | |
| Thiraviyam et al. | Head and Neck | |
| Aarthi et al. | Head and Neck |